Actemra (tocilizumab), a biologic treatment for rheumatoid arthritis, has been given an emergency use authorisation in the US for the treatment of adults and children two years and older who have been hospitalised with Covid-19. The approval was based on data from four clinical trials, one of which was RECOVERY, a trial led by researchers in the UK.
